Dapagliflozin And Metformin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 72205-435

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Dapagliflozin And Metformin Hydrochloride (NDC 72205-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dapa-met-10mg-1000mg-30-pack (Dapa Met 10mg 1000mg 30 Pack)

These are Dapagliflozin and Metformin HCI Extended-Release Tablets with a dosage of 10 mg dapagliflozin and 1,000 mg metformin hydrochloride per tablet. The tablets should not be crushed, cut, or chewed and must be swallowed whole. The usual dosage information can be found in the package insert. Store the tablets at a temperature between 20°C to 25°C (66°F to 77°F) with excursions permitted between 15°C and 30°C (59°F to 86°F). It is advised not to use if the printed inner seal of the bottle is broken or missing. Distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

FDA Label Image

Dapa-met-10mg-1000mg-400-pack (Dapa Met 10mg 1000mg 400 Pack)

This is a prescription medication called Dapagliflozin and Metformin HCI Extended-Release Tablets, each containing 10 mg of dapagliflozin and 1,000 mg of metformin hydrochloride. The tablets are not meant to be crushed, cut, or chewed, and should be swallowed whole. The usual dosage information can be found in the package insert. It is important to store the medication at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The medication should not be used if the printed inner seal of the bottle is broken or missing. This product is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. The package includes 400 tablets and is not child resistant. It is recommended to keep this medication out of the reach of children.*

FDA Label Image

Dapa-met-10mg-1000mg-60-pack (Dapa Met 10mg 1000mg 60 Pack)

This is a description of a medication called Dapagliflozin and Metformin HCI Extended-Release Tablets. Each tablet contains 10 mg of dapagliflozin and 1,000 mg of metformin hydrochloride. The tablets should not be crushed, cut, or chewed, and must be swallowed whole. The usual dosage instructions can be found in the package insert. The medication should be stored at a temperature between 20°C and 25°C. It is important not to use the medication if the printed inner seal of the bottle is broken or missing. The medication is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in the United States. The product includes 60 tablets per bottle and is labeled with an NDC number for easy identification.*

FDA Label Image

Dapa-met-10mg-500mg-30-pack (Dapa Met 10mg 500mg 30 Pack)

This text is a label for a medication named Dapagliflozin and Metformin HCI Extended-Release Tablets. It contains important information such as the dosage, storage instructions, manufacturer details, and a reminder for pharmacists to dispense the medication guide to each patient. The tablets should not be crushed, cut, or chewed, and must be swallowed whole. It also provides details on the dosage, storage conditions, and what to do if the printed seal is broken on the bottle.*

FDA Label Image

Dapa-met-10mg-500mg-500-pack (Dapa Met 10mg 500mg 500 Pack)

This text is a medication label for Dapagliflozin and Metformin HCI Extended-Release Tablets, each tablet containing 10 mg of dapagliflozin and 500 mg of metformin hydrochloride. The tablets should not be crushed, cut, or chewed, and must be swallowed whole. The usual dosage information can be found in the package insert. The storage temperature range is between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). The medication is distributed by Novadoz Pharmaceuticals LLC.*

FDA Label Image

Dapa-met-5mg-1000mg-30-pack (Dapa Met 5mg 1000mg 30 Pack)

The text is a label for a medication called Dapagliflozin and Metformin HCI Extended-Release Tablets. Each tablet contains 5 mg dapagliflozin and 1,000 mg metformin hydrochloride USP. The tablets should be swallowed whole and not crushed, cut, or chewed. It provides storage instructions, dosage information, manufacturer details, and contact information for Novadoz Pharmaceuticals LLC. The medication is distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. Indicated M.L.No.: 5IMNITS/2014/FIG. Printed inner seals are not to be used if they are broken or missing.*

FDA Label Image

Dapa-met-5mg-1000mg-400-pack (Dapa Met 5mg 1000mg 400 Pack)

This is a prescription medication containing Dapagliflozin and Metformin HCI in extended-release tablets. Each tablet has 5 mg of dapagliflozin and 1,000 mg of metformin hydrochloride. It is important to swallow the tablets whole and not crush, cut, or chew them. The usual dosage and storage instructions are provided in the package insert. The medication should be kept at 20°C to 25°C (68°F to 77°F). The manufacturer is MSN Laboratories Private Limited in India, and it is distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. Pharmacists are advised to dispense the medication with the accompanying Medication Guide to each patient.*

FDA Label Image

Dapa-met-5mg-1000mg-60-pack (Dapa Met 5mg 1000mg 60 Pack)

This is a prescription medicine with the NDC 72205-435-03, containing Dapagliflozin and Metformin HCI Extended-Release Tablets with a strength of 5mg/1,000 mg. It is advised not to crush, cut, or chew the tablets, and they should be swallowed whole. Each tablet contains 5 mg of dapagifiozin and 1,000 mg of metformin hydrochloride. The package insert should be consulted for full dosage information. The tablets should be stored at 20°C to 25°C (68°F to 77°F). This medication is manufactured by MSN Laboratories in India and distributed by Novadoz Pharmaceuticals in Piscataway, NJ.*

FDA Label Image

Dapa-met-5mg-500mg-30-pack (Dapa Met 5mg 500mg 30 Pack)

This is a prescription medication with the name "Dapagliflozin and Metformin HCI Extended-Release Tablets" containing 5 mg of dapagliflozin and 500 mg of metformin hydrochloride. The tablets should not be crushed, cut, or chewed and must be swallowed whole. Each bottle contains 30 tablets and should be stored at 20°C to 25°C. The medication guide should be provided to each patient. For full dosage information, refer to the package insert. This medication is distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

FDA Label Image

Dapa-met-5mg-500mg-500-pack (Dapa Met 5mg 500mg 500 Pack)

This is a description of Dapagliflozin and Metformin HCI Extended-Release Tablets containing 5mg/500mg. The tablets must not be crushed, cut, or chewed and should be swallowed whole. Each tablet consists of 5 mg dapagliflozin and 500 mg metformin hydrochloride USP. The usual dosage information can be found in the package insert. Storage is recommended at 20°C to 25°C (68°F to 77°F). The medication should not be used if the printed inner seal is broken or missing. Manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

FDA Label Image

Dapa-met-dapagliflozin-structure (Dapa Met Dapagliflozin Structure)

FDA Label Image

Figure-01 (Dapa Met Figure 01)

This appears to be a data table showing values related to Urinary Glucose testing with Dapagliflozin dose (mg) and related observations for healthy subjects and subjects with T2DM. The table seems to include values such as plot data points, fitted lines for healthy subjects and subjects with T2DM, and some numerical data.*

FDA Label Image

Figure-02 (Dapa Met Figure 02)

FDA Label Image

Figure-03 (Dapa Met Figure 03)

This description presents information on the adjusted mean change from baseline HbA1c (%) over a 24-week period in a study comparing the effects of placebo plus metformin versus dapagliflozin 10 mg plus metformin. The data includes values for the adjusted mean change from baseline based on a longitudinal repeated measures model for subjects who completed the short-term period without rescue. The graphs illustrate these values along with confidence intervals, providing insights into the impact of the different treatments on HbA1c levels over time.*

FDA Label Image

Fig4 (Dapa Met Figure 04)

FDA Label Image

Fig5 (Dapa Met Figure 05)

This text appears to show data related to a clinical trial comparing the effectiveness of Dapagliflozin versus a Placebo treatment. The data includes the number of patients at risk for each treatment over different time points (in months) from randomization. This information could be useful for analyzing the progression of events and outcomes in the study.*

FDA Label Image

Dapa-met-figure-06 (Dapa Met Figure 06)

FDA Label Image

Dapa-met-figure-07a (Dapa Met Figure 07a)

This data appears to show the comparison between the drug Dapagliflozin and a Placebo in terms of the percentage of patients experiencing an event over time. The provided information includes the number of patients at risk for each treatment group at various time points, along with the hazard ratio (HR) of Dapagliflozin versus Placebo. The HR value indicates a significant difference favoring Dapagliflozin as it is less than 1. The data spans over a period of 24 months from randomization.*

FDA Label Image

Dapa-met-figure-07b (Dapa Met Figure 07b)

FDA Label Image

Dapa-met-figure-08 (Dapa Met Figure 08)

FDA Label Image

Dapa-met-metformin-structure (Dapa Met Metformin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.